Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Certara (NASDAQ: CERT) released preliminary Q4 and full-year 2024 financial results, reporting annual revenue of $384.4 million, up 8% from 2023. Q4 revenue reached $99.7 million, showing 13% growth year-over-year.
The company's software segment demonstrated strong performance with Q4 revenue of $41.6 million (+24%) and full-year revenue of $155.0 million (+18%). Services revenue grew more modestly, with Q4 at $58.1 million (+7%) and full-year at $229.4 million (+3%).
Total bookings for 2024 increased 11% to $445.3 million, with software bookings growing 24% to $169.4 million and services bookings up 4% to $275.9 million. The company confirmed its adjusted EBITDA guidance range of $120-124 million for 2024. The results include contribution from Chemaxon, acquired on October 1, 2024, which added $5.9 million in revenue and $11.0 million in bookings.
Certara (NASDAQ: CERT) ha pubblicato i risultati finanziari preliminari per il quarto trimestre e per l'intero anno 2024, riportando un fatturato annuo di 384,4 milioni di dollari, in aumento dell'8% rispetto al 2023. Il fatturato del quarto trimestre ha raggiunto 99,7 milioni di dollari, con una crescita del 13% rispetto all'anno precedente.
Il segmento software dell'azienda ha mostrato una forte performance con un fatturato del quarto trimestre di 41,6 milioni di dollari (+24%) e un fatturato annuale di 155,0 milioni di dollari (+18%). Il fatturato dei servizi è cresciuto in modo più modesto, con 58,1 milioni di dollari nel quarto trimestre (+7%) e 229,4 milioni di dollari per l'intero anno (+3%).
Gli ordinativi totali per il 2024 sono aumentati dell'11% raggiungendo 445,3 milioni di dollari, con gli ordinativi del software in crescita del 24% a 169,4 milioni di dollari e quelli dei servizi in aumento del 4% a 275,9 milioni di dollari. L'azienda ha confermato una previsione di EBITDA rettificato compresa tra 120 e 124 milioni di dollari per il 2024. I risultati includono il contributo di Chemaxon, acquisito il 1° ottobre 2024, che ha aggiunto 5,9 milioni di dollari in fatturato e 11,0 milioni di dollari in ordinativi.
Certara (NASDAQ: CERT) publicó los resultados financieros preliminares para el cuarto trimestre y para todo el año 2024, informando unos ingresos anuales de 384,4 millones de dólares, lo que supone un aumento del 8% en comparación con 2023. Los ingresos del cuarto trimestre alcanzaron 99,7 millones de dólares, mostrando un crecimiento del 13% interanual.
El segmento de software de la empresa demostró un fuerte rendimiento con ingresos del cuarto trimestre de 41,6 millones de dólares (+24%) y unos ingresos anuales de 155,0 millones de dólares (+18%). Los ingresos por servicios crecieron de manera más modesta, con 58,1 millones de dólares en el cuarto trimestre (+7%) y 229,4 millones de dólares para todo el año (+3%).
Las reservas totales para 2024 aumentaron un 11% a 445,3 millones de dólares, con reservas de software que crecieron un 24% a 169,4 millones de dólares y reservas de servicios que subieron un 4% a 275,9 millones de dólares. La empresa confirmó su rango de guía para EBITDA ajustado de 120 a 124 millones de dólares para 2024. Los resultados incluyen la contribución de Chemaxon, adquirida el 1 de octubre de 2024, que agregó 5,9 millones de dólares en ingresos y 11,0 millones de dólares en reservas.
Certara (NASDAQ: CERT)는 2024년 4분기 및 연간 재무 결과를 발표하며, 연간 수익이 3억 8440만 달러로 2023년 대비 8% 증가했다고 밝혔습니다. 4분기 수익은 9천 970만 달러에 달하며, 이는 전년 대비 13% 성장한 수치입니다.
회사의 소프트웨어 부문은 4분기 수익이 4160만 달러 (+24%) 및 연간 수익이 1억 5500만 달러 (+18%)로 강력한 성과를 나타냈습니다. 서비스 부문의 수익은 좀 더 완만하게 성장하여, 4분기에는 5810만 달러 (+7%), 연간으로는 2억 2940만 달러 (+3%)를 기록했습니다.
2024년 총 예약 주문은 11% 증가하여 4억 4530만 달러에 달하며, 소프트웨어 예약 주문은 24% 증가하여 1억 6940만 달러, 서비스 예약 주문은 4% 증가하여 2억 7590만 달러에 도달했습니다. 회사는 2024년 조정 EBITDA 가이던스 범위를 1억 2000만 달러에서 1억 2400만 달러로 확인했습니다. 이 결과에는 2024년 10월 1일에 인수한 Chemaxon의 기여가 포함되어 있으며, 이는 590만 달러의 수익과 1100만 달러의 예약을 추가했습니다.
Certara (NASDAQ: CERT) a publié des résultats financiers préliminaires pour le quatrième trimestre et l'année 2024, annonçant un chiffre d'affaires annuel de 384,4 millions de dollars, en hausse de 8 % par rapport à 2023. Le chiffre d'affaires du quatrième trimestre a atteint 99,7 millions de dollars, enregistrant une croissance de 13 % d'une année sur l'autre.
Le segment logiciel de l'entreprise a montré de fortes performances avec un chiffre d'affaires du quatrième trimestre de 41,6 millions de dollars (+24 %) et un chiffre d'affaires total de 155,0 millions de dollars (+18 %). Les revenus des services ont crû de manière plus modeste, avec 58,1 millions de dollars au quatrième trimestre (+7 %) et un total annuel de 229,4 millions de dollars (+3 %).
Les réservations totales pour 2024 ont augmenté de 11 % pour atteindre 445,3 millions de dollars, avec des réservations de logiciels en hausse de 24 % à 169,4 millions de dollars et des réservations de services augmentant de 4 % à 275,9 millions de dollars. L'entreprise a confirmé sa prévision d'EBITDA ajusté pour 2024, qui se situe entre 120 et 124 millions de dollars. Les résultats incluent la contribution de Chemaxon, acquis le 1er octobre 2024, qui a ajouté 5,9 millions de dollars de chiffre d'affaires et 11,0 millions de dollars de réservations.
Certara (NASDAQ: CERT) hat die vorläufigen finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht, mit einem Jahresumsatz von 384,4 Millionen US-Dollar, was einem Anstieg von 8% im Vergleich zu 2023 entspricht. Der Umsatz im vierten Quartal erreichte 99,7 Millionen US-Dollar und zeigt ein Wachstum von 13% im Jahresvergleich.
Das Software-Segment des Unternehmens zeigte eine starke Leistung mit einem Quartalsumsatz von 41,6 Millionen US-Dollar (+24%) und einem Jahresumsatz von 155,0 Millionen US-Dollar (+18%). Der Umsatz aus Dienstleistungen wuchs gemäßigter, mit 58,1 Millionen US-Dollar im vierten Quartal (+7%) und 229,4 Millionen US-Dollar im gesamten Jahr (+3%).
Die Gesamtbuchungen für 2024 stiegen um 11% auf 445,3 Millionen US-Dollar, wobei die Buchungen für Software um 24% auf 169,4 Millionen US-Dollar wuchsen und die Buchungen für Dienstleistungen um 4% auf 275,9 Millionen US-Dollar stiegen. Das Unternehmen bestätigte seine angepasste EBITDA-Prognose für 2024 in einer Spanne von 120 bis 124 Millionen US-Dollar. Die Ergebnisse beinhalten den Beitrag von Chemaxon, das am 1. Oktober 2024 übernommen wurde und 5,9 Millionen US-Dollar Umsatz und 11,0 Millionen US-Dollar Buchungen beisteuerte.
- Q4 revenue growth of 13% year-over-year to $99.7 million
- Strong software segment performance with 24% Q4 revenue growth
- Total bookings increased 11% to $445.3 million for 2024
- Software bookings showed robust 24% growth to $169.4 million
- Services revenue growth slowed to 3% for full-year 2024
- Services bookings showed modest 4% growth for 2024
Insights
Certara's preliminary Q4 2024 results showcase robust performance with notable growth metrics. Total revenue reached
The
The software-to-services revenue mix is gradually shifting toward higher-margin software business, improving from
The drug development technology sector's dynamics are clearly reflected in Certara's results. The
The services segment's modest growth of
The strategic acquisition of Chemaxon enhances Certara's competitive position in the molecular modeling space, a critical component of modern drug discovery processes. The immediate contribution to both revenue and bookings validates the acquisition's strategic rationale and timing.
Full-Year 2024 Revenue of
Confirms Adjusted EBITDA within Guidance Range of
RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results.
Preliminary financials for the fourth quarter of 2024 are expected to be as follows:
- Revenue of
$99.7 million , compared to$88.0 million in the fourth quarter of 2023, representing growth of13% .- Software revenue of
$41.6 million , compared to$33.6 million in the fourth quarter of 2023, representing growth of24% . - Services revenue of
$58.1 million , compared to$54.4 million in the fourth quarter of 2023, representing growth of7% .
- Software revenue of
- Bookings of
$144.5 million , compared to$118.9 million in the fourth quarter of 2023, representing growth of22% .- Software bookings of
$59.7 million , compared to$43.3 million in the fourth quarter of 2023, representing growth of38% . - Services bookings of
$84.9 million , compared to$75.6 million in the fourth quarter of 2023, representing growth of12% .
- Software bookings of
- Preliminary revenue and bookings include Chemaxon revenue of
$5.9 million and bookings of$11.0 million . Certara completed the acquisition of Chemaxon on October 1, 2024.
Preliminary financials for the full year of 2024 are expected to be as follows:
- Revenue of
$384.4 million , compared to$354.3 million in 2023, representing growth of8% .- Software revenue of
$155.0 million , compared to$131.7 million in 2023, representing growth of18% . - Services revenue of
$229.4 million , compared to$222.7 million in 2023, representing growth of3% .1
- Software revenue of
- Bookings of
$445.3 million , compared to$402.3 million in 2023, representing growth of11% .- Software bookings of
$169.4 million , compared to$136.9 million in 2023, representing growth of24% . - Services bookings of
$275.9 million , compared to$265.4 million in 2023, representing growth of4% .
- Software bookings of
Certara also continues to expect adjusted EBITDA for the full year of 2024 between its previously disclosed guidance range of
These preliminary fourth quarter and full year 2024 results are unaudited and subject to the finalization of the Company’s regular financial and accounting procedures. As a result, these preliminary estimates may differ from the actual results that will be reflected in the Company’s consolidated financial statements for the fourth quarter and full year when they are completed and publicly disclosed, and any changes may be material. The Company’s expectations with respect to its unaudited results for the periods discussed above are based on management’s current estimates.
Certara management will present at the 43rd Annual J.P. Morgan Healthcare Conference today, January 15th, 2025, at 5:15PM PT. The presentation deck will be available on the Company’s IR website.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries.
Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s fourth quarter and full-year 2024 results. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange fluctuation and adverse developments in the financial services industry; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers; consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the impact of acquisitions and our ability to successfully integrate such acquisitions; the occurrence of natural disasters and epidemic diseases; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; our ability to accurately estimate costs associated with its fixed-fee contracts; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; lower utilization rates by our employees as a result of natural disasters and epidemic diseases; risks related to our contracts with government customers; our ability to sustain recent growth rates; our ability to successfully operate a global business; our ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; our ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; future capital needs; the ability of our bookings to accurately predict future revenue and our ability to realize revenue on bookings; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity; our ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; risks relating to the use of artificial intelligence and machine learning in our products and services; our ability to adequately enforce or defend ownership and use of our intellectual property and other proprietary rights; any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; our ability to meet obligations under indebtedness and have sufficient capital to operate our business; any limitations on our ability to pursue business strategies due to restrictions under our current or future indebtedness; any additional impairment of goodwill or other intangible assets; our ability to use our net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; any inability to design, implement, and maintain effective internal controls or inability to remediate any internal controls deemed ineffective; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-Q filed by the Company with the SEC on November 6, 2024 and the Form 10-K filed by the Company with the SEC on February 29, 2024, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.
A Note on Non-GAAP Financial Measures
This press release contains “non-GAAP measures” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measure adjusted EBITDA, which is not a recognized term under GAAP. This measure should not be considered an alternative to net income (loss) derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of this measure has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
Management uses non-GAAP measures such as adjusted EBITDA to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.
Management believes that disclosing adjusted EBITDA is helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, adjusted EBITDA is frequently used by analysts, investors, and other interested parties to evaluate and assess performance.
Please note that the Company has not reconciled the expected adjusted EBITDA ranges included in this press release to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the unavailability at this time of certain adjustments, including in particular tax-related adjustments, which remain subject to finalization of the Company’s regular financial and accounting procedures.
Adjusted EBITDA represents net income excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance.
In evaluating adjusted EBITDA, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
Contacts:
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
Pan Communications
certara@pancomm.com
1 Includes
FAQ
What was Certara's (CERT) revenue growth in Q4 2024?
How much did Certara's (CERT) software revenue grow in 2024?
What was Certara's (CERT) total bookings value for 2024?
How much revenue did Chemaxon contribute to Certara (CERT) in Q4 2024?
What is Certara's (CERT) adjusted EBITDA guidance range for 2024?
